[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351762-105":59,"doc-detail-351762-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-shen-ling-lian-xia-granule-combined-with-neoadjuvant-chemotherapy-in-patients-with-triple-negative-breast-cancer-protocol-for-a-randomized-double-blind-multicenter-clinical-trial","Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With TripleNegative Breast Cancer - Protocol for a Randomized, DoubleBlind, Multicenter Clinical Trial","","Neoadjuvant chemotherapy (NAC) is a key systemic treatment for triple-negative breast cancer (TNBC), aiming to reduce recurrence and improve survival while converting unresectable tumors to resectable ones. Shen-Ling-Lian-Xia Granules (SLLXG), an in-house preparation from Longhua Hospital, has shown potential benefits postoperatively, but its clinical evidence as an adjunct to NAC for TNBC is not established. This protocol evaluates SLLXG’s synergistic effects with NAC and seeks patient subgroups likely to benefit, using a randomized double-blind multicenter design.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-shen-ling-lian-xia-granule-combined-with-neoadjuvant-chemotherapy-in-patients-with-triple-negative-breast-cancer-protocol-for-a-randomized-double-blind-multicenter-clinical-trial/351762/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-shen-ling-lian-xia-granule-combined-with-neoadjuvant-chemotherapy-in-patients-with-triple-negative-breast-cancer-protocol-for-a-randomized-double-blind-multicenter-clinical-trial/351762.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of combining SLLXG with neoadjuvant chemotherapy for TNBC in this trial protocol?","Question",{"text":112,"@type":113},"The study analyzes how SLLXG affects the efficacy of NAC for TNBC, evaluates potential synergistic effects, and identifies candidate patient populations that may benefit from SLLXG alongside NAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How will participants be assigned in the study?",{"text":117,"@type":113},"A total of 306 TNBC patients will be recruited and randomly assigned to receive NAC plus either SLLXG or an SLLXG placebo in a double-blind design.",{"name":119,"@type":110,"acceptedAnswer":120},"What endpoints will be used to assess efficacy and safety outcomes?",{"text":121,"@type":113},"The primary efficacy endpoint is pathological complete response. Secondary efficacy endpoints include objective response rate, clinical benefit rate, Miller-Payne grading, residual cancer burden, and immune-related measures such as peripheral blood lymphocytes and stromal tumor-infiltrating lymphocytes, with quality-of-life assessment using EORTC QLQ-C30.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351762,1790119512,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","JMIR RESEARCH PROTOCOLS Ren et al  \nProtocol  \nEfficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With TripleNegative Breast Cancer: Protocol for a Randomized, DoubleBlind, Multicenter Clinical Trial  \n\n| Yuanyuan Ren 1,2* , MD; Shuai Yuan3* , MD; Youyang Shi2* , MD, PhD; Lichen Tang4 , MD; Tian Li5 , MD; Rui Yang6 , MD; Kaigang Xie7 , MD; Xiaoqing Zhang8 , MD; Jue Chen9 , MD; Jinhui Hu 10 , MD; Sheng Liu2 , MD, PhD |\n| --- |\n| 1School of Clinical Medicine, Jiangxi University of Chinese Medicine, Jiangxi, China\u003Cbr>2Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China 3International Peace Maternity & Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 4Fudan University Shanghai Cancer Center, Shanghai, China\u003Cbr>5Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine (Baoshan Hospital, Shanghai University of Traditional Chinese Medicine), Shanghai, China\u003Cbr>6Shanxi Cancer Hospital, Taiyuan, China\u003Cbr>7Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, China 8Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangsu, China\u003Cbr>9Affiliated Hospital of Yangzhou University, Yangzhou, China\u003Cbr>10First Affiliated Hospital of Hunan University of Chinese Medicine, Hunan, China\u003Cbr>*these authors contributed equally\u003Cbr>Corresponding Author:\u003Cbr>Sheng Liu, MD, PhD\u003Cbr>Department of Breast Surgery\u003Cbr>Longhua Hospital, Shanghai University of Traditional Chinese Medicine\u003Cbr>725 Wanping South Rd, Xuhui District Shanghai 200032\u003Cbr>China\u003Cbr>Phone: 86 18917763005\u003Cbr>Email: [lshtcm@163.com](lshtcm@163.com)\u003Cbr>Abstract |\n\nBackground: Neoadjuvant chemotherapy (NAC) is a crucial component of systemic treatment for triple-negative breast cancer (TNBC), serving as an effective means to reduce recurrence rates and improve survival outcomes. It not only maximizes the extent of resectable tumors but also converts inoperable tumors into operable ones . Shen-Ling-Lian-Xia Granules (SLLXG) is an in-house preparation developed by Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine. Formulated by Professor Liu Sheng, the fifth-generation inheritor of the Shanghai Gu School of Surgery, based on extensive clinical experience treating breast cancer, this compound has been clinically proven to improve postoperative symptoms in patients with TNBC, enhance immunity, reduce recurrence and metastasis, and prolong disease-free survival. However, clinical evidence regarding its efficacy in enhancing the therapeutic effect of NAC for TNBC remains to be established.  \nObjective: This study aims to analyze the impact of SLLXG on the efficacy of NAC for TNBC, evaluate its synergistic effect on NAC, and identify potential beneficiary populations for SLLXG in treating TNBC. It seeks to establish a standardized diagnostic and treatment protocol for broader clinical implementation.  \nMethods: This study will recruit 306 patients diagnosed with TNBC. Patients will be randomly assigned to two groups: one receiving NAC combined with SLLXG treatment, and the other receiving NAC combined with SLLXG placebo treatment. The primary efficacy endpoint was pathological complete response. Secondary efficacy endpoints included objective response rate, clinical benefit rate, Miller-Payne grading for breast cancer, residual cancer burden, peripheral blood lymphocyte levels, stromal tumor-infiltrating lymphocytes in the tumor region stroma, and European Organisation for Research and Treatment  \n[https://www.researchprotocols.org/2026/1/e91475](https://www.researchprotocols.org/2026/1/e91475) JMIR Res Protoc 2026 | vol. 15 | e91475 | p. 1  \n(page number not for citation purposes)  \nJMIR RESEARCH PROTOCOLS Ren et al  \nof Cancer Quality of Life Questionnaire (EORTC QLQ-C30; version 3.0) . Evaluation timepoints will occur after completion of cycles 2, 4, 6,","cbCairwQ4ScqqbuN","https://ap.wps.com/l/cbCairwQ4ScqqbuN","pdf",294905,13,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background","[{\"question\":\"What is the purpose of combining SLLXG with neoadjuvant chemotherapy for TNBC in this trial protocol?\",\"answer\":\"The study analyzes how SLLXG affects the efficacy of NAC for TNBC, evaluates potential synergistic effects, and identifies candidate patient populations that may benefit from SLLXG alongside NAC.\"},{\"question\":\"How will participants be assigned in the study?\",\"answer\":\"A total of 306 TNBC patients will be recruited and randomly assigned to receive NAC plus either SLLXG or an SLLXG placebo in a double-blind design.\"},{\"question\":\"What endpoints will be used to assess efficacy and safety outcomes?\",\"answer\":\"The primary efficacy endpoint is pathological complete response. Secondary efficacy endpoints include objective response rate, clinical benefit rate, Miller-Payne grading, residual cancer burden, and immune-related measures such as peripheral blood lymphocytes and stromal tumor-infiltrating lymphocytes, with quality-of-life assessment using EORTC QLQ-C30.\"}]","Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With TripleNegative Breast Cancer - Protocol for a Randomized, DoubleBlind, Multicenter Clinical Trial | PDF",1790095769,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20a676561edae4e00675f8c5fcc756df.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/636d41223e376a4ee42db295ede75987.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a49fc0119be61e4bd6278de9b127d0dd.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2ad5354f377e4251a55d5d68ea6e2d8.webp",980,1385]